What Caused Sarepta Therapeutics To Crash 29% in April
May 03, 2016 at 12:20 PM EDT
SOURCE: SAREPTA THERAPEUTICS What: A meeting of the FDA's Peripheral and Central Nervous System Advisory Committee last month to discuss approving the company's drug for a form of muscular dystrophy sentshares of Sarepta Therapeutics tumbling 29% in April, according to data from S&P Global Market Intelligence .
